Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00176_DB00321_nanopub.RAB0H5SjA2D0fpFvAWZQUwUKRXMkd5-UgSguF6U3EK-iU#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00176_DB00321 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00176_DB00321 label "DDI between Fluvoxamine and Amitriptyline - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluvoxamine is initiated, discontinued or dose changed. [drugbank_resource:DB00176_DB00321]" assertion.
- drugbank_resource:DB00176_DB00321 identifier "drugbank_resource:DB00176_DB00321" assertion.
- drugbank_resource:DB00176_DB00321 title "DDI between Fluvoxamine and Amitriptyline - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluvoxamine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00321 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB00321 assertion.
- drugbank:DB00176 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB00321 assertion.